Document text
Principal Investigator: SUSAN H ESHLEMAN
Organization: JOHNS HOPKINS UNIVERSITY
Fiscal Year: 2020
Award: $167,145
Funding agency: National Institute of Allergy and Infectious Diseases
PROJECT SUMMARY
This project will provide laboratory support for a large, cross-sectional COVID-19 seroprevalence study that will
be conducted in 23-25 communities in the United States: the SARS-CoV-2 Seroprevalence Study (COVID-19
Prevention Trials Network [CoVPN] 5002). The CoVPN 5002 study will include collection of data and specimens
from up to 98,000 persons, including persons living in nursing homes and assisted living facilities, persons
attending clinics, and persons living in study communities. The study will include children (ages 2 months and
older) and adults. Participants will be tested for COVID-19 in real time using SARS-CoV-2 RNA assays.
Seroprevalence will be assessed retrospectively using stored specimens from all participants using a sensitive
and specific SARS-CoV-2 IgG assay (Abbott ARCHITECT COVID-19 IgG test). A subset of specimens from
CoVPN 5002 will also be used to evaluate the performance of diagnostic and serologic SARS-CoV-2 assays
using alternate specimen types (saliva and dried blood spots). Collection of these sample types is simpler and
less invasive than collection of nasal swabs or collection of blood samples by phlebotomy. This project will also
use of specialized assays to evaluate the serologic response to SARS-CoV-2. This will include use of a massively
multiplexed antibody profiling assay (CoronaScan) to measure antibody binding to SARS-CoV-2 peptides
spanning the viral genome. This analysis will provide information on the fine specificity of the antibody response
to SARS-CoV-2 and reactivity to other coronaviruses and other viruses that cause respiratory illnesses. This
testing may also identify participants who have false positive or false negative test results using the ARCHITECT
COVID-19 IgG test. Specimens that have antibodies to the SARS-CoV-2 spike protein (identified using the
CoronaScan assay) will be further assessed using a phenotypic recombinant viral neutralization assay
(PhenoSense Anti-SARS-CoV-2 Neutralizing Antibody Assay). This analysis may identify viral epitopes
associated with viral neutralization and may also identify demographic and clinical factors associated with the
presence of neutralizing antibodies. Specimens from CoVPN 5002 will also be used for further development and
evaluation of a novel, massively multiplexed pathogen detection assay, cRASL-Seq, that does not require RNA
extraction. Findings from this research will inform the design of clinical trials for SARS-CoV-2 prevention and
treatment by providing information about the seroprevalence of COVID-19 in diverse geographic regions and
participants groups, including asymptomatic and symptomatic individuals, children and adults in the general
population, and adults at increased risk for COVID-19.
Terms: <0-11 years old><2019 novel coronavirus><2019-nCoV><21+ years old><7S Gamma Globulin><Address><Adult><Adult Human><African American><Afro American><Afroamerican><Age><Antibodies><Antibody Response><Antibody Specificity><Antigenic Determinants><Assay><Assisted Living Facilities><Binding><Binding Determinants><Bioassay><Biologic Assays><Biological Assay><Black Populations><Blood><Blood Reticuloendothelial System><Blood Sample><Blood specimen><COPD><COVID-19><COVID-19 epidemic><COVID-19 pandemic><COVID19><COVID19 epidemic><COVID19 pandemic><Cardiac Diseases><Cardiac Disorders><Child><Child Youth><Children (0-21)><Chronic Kidney Failure><Chronic Obstruction Pulmonary Disease><Chronic Obstructive Airway Disease><Chronic Obstructive Lung Disease><Chronic Obstructive Pulmonary Disease><Chronic Renal Disease><Chronic Renal Failure><Cities><Clinic><Clinical><Clinical Trials Design><Cohort Studies><Collection><Communities><Concurrent Studies><Coronaviridae><Coronavirus><Country><Data><Data Collection><Detection><Development><Diabetes Mellitus><Diagnosis><Diagnostic><Diagnostic tests><Disease><Disorder><Elderly><Epitopes><Evaluation><Future><General Population><General Public><Genotype><Geographic Area><Geographic Locations><Geographic Region><Geographical Location><HIV prevention trials network><Heart Diseases><IgG><Immunoglobulin G><Individual><Infection><Laboratories><Measures><Medical><Methods><Molecular Interaction><Morbidity><Morbidity - disease rate><Nasal><Nasal Passages Nose><Non-Polyadenylated RNA><Nose><Nursing Homes><Obesity><Participant><Pathogen detection><Peptides><Performance><Persons><Phenotype><Phlebotomy><Play><Populations at Risk><Prevalence><Prevention><Prevention trial><Proteins><Public Health><RNA><RNA Gene Products><Recombinants><Research><Research Specimen><Respiratory System, Nose, Nasal Passages><Ribonucleic Acid><Risk><Role><SARS-CoV-2><SARS-CoV2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Saliva><Sampling><Serologic><Serologic tests><Serological><Serological Tests><Seroprevalences><Severe acute respiratory syndrome coronavirus 2><Specimen><Spottings><Swab><Technology><Test Result><Testing><United States><Validation><Venous blood sampling><Viral><Viral Genome><Virus><Whole Blood><Work><Wuhan coronavirus><adiposity><adulthood><advanced age><ages><assisted living><assistive living><assistive living facilities><base><black American><burden of disease><burden of illness><children><childrens'><chronic kidney disease><corona virus><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019><coronavirus disease 2019 epidemic><coronavirus disease 2019 pandemic><corpulence><corpulency><corpulentia><developmental><diabetes><disease burden><elders><experience><geographic site><geriatric><heart disorder><insight><late life><later life><mortality><neutralizing antibody><novel><nursing home><obese><obese people><obese person><obese population><older adult><older person><pandemic><pandemic disease><pathogen><programs><research study><respiratory><response><sample collection><senior citizen><serology><social role><specimen collection><time use><virus genome><years of life lost to disability><years of life lost to disease><youngster>